- The key vendors in the Global Asthma Market are AstraZeneca plc, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc. and Novartis AG.
London, 26 August 2014: TechNavio, an independent tech-focused global research firm, announced today the publication of its market research report on the Global Asthma Market 2014-2018. One of the potential trends in the market is the use of combination therapies for the treatment of asthma patients, which can improve patient condition in persistent asthma. These act via reduction of the symptoms by controlling inflammation in the respiratory tract. The Global Asthma market is expected to post a CAGR of 4.50 percent during 2013-2018.
“Biologics are increasingly becoming the preferred choice to treat asthma. They act by blocking the interleukins, which cause inflammation in the respiratory tract. Currently, Xolair (omalizumab) by Genentech and Novartis is the only approved biologic drug for the treatment of asthma,” says Faisal Ghaus, Vice President of TechNavio Research.
To define the market conditions in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
